Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | DPYD | Q12882 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HBB | P68871 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1052427 | 0.81 | GAA (0.48) | GAALMNADPYDALDH1A1MAPT | |
| SCHEMBL127493 | 0.80 | KDM3B (0.64) | GAALMNADPYDALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL11439523 | 0.78 | KDM3B (0.62) | GAALMNADPYDALDH1A1MAPT | |
| SCHEMBL1210894 | 0.78 | GAA (0.50) | GAALMNADPYDALDH1A1MAPT | |
| SCHEMBL190958 | 0.78 | GAA (0.50) | GAALMNADPYDALDH1A1MAPT | |
| Water SCHEMBL4487821 | 0.78 | KDM3B (0.62) | GAALMNADPYDALDH1A1MAPT | |
| SCHEMBL119748 | 0.77 | GAA (0.48) | GAALMNADPYDALDH1A1MAPT | |
| SCHEMBL1259773 | 0.76 | DPYD (0.44) | GAALMNADPYDALDH1A1MAPT | |
| SCHEMBL1259771 | 0.76 | DPYD (0.44) | GAALMNADPYDALDH1A1MAPT | |
| SCHEMBL12050193 | 0.74 | GAA (0.45) | GAALMNADPYDALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667635-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667635-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2023-06-06 | — | — | US | disclosed |
| US-20220009921-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2022-01-13 | — | — | US | disclosed |
| CN-106674136-B | Pyrimidine anti-tumor compounds and preparation method thereof | 中国医科大学 | 2019-07-02 | — | — | CN | disclosed |
| CN-106674136-A | Anti-tumor pyrimidine compounds and preparation method thereof | 中国医科大学 | 2017-05-17 | — | — | CN | disclosed |
| CN-104650045-B | Preparation method of avanafil | 苏州旺山旺水生物医药有限公司 | 2017-04-19 | — | — | CN | disclosed |
| EP-1051655-B1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | ISTA PHARMACEUTICALS INC (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1051655-A4 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | ISTA PHARMACEUTICALS INC (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20010016731-A1 | Methods and apparatus for accelerated orthokeratology | DEVORE DALE (US) | 2001-08-23 | — | — | US | disclosed |
| US-6161544-A | Methods for accelerated orthokeratology | KERATOFORM, INC. (US) | 2000-12-19 | — | — | US | disclosed |
| EP-1051655-A1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | Ista Pharmaceuticals, Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999039238-A1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | KERATOFORM, INC. (US) | 1999-08-05 | — | — | WO | disclosed |
| US-4202900-A | Derivatives of penam-3-carboxylic acid and a pharmaceutical composition containing the same | CIBA-GEIGY CORPORATION (US) | 1980-05-13 | — | — | US | disclosed |
| US-4118217-A | POSTEMERGENCE HERBICIDES | FARMLAND INDUSTRIES, INCORPORATED (US) | 1978-10-03 | — | — | US | disclosed |
| US-4015000-A | 6-Acylamino-penam-3-carboxylic and 7-acylamino-3-cephem-4-carboxylic acids | CIBA-GEIGY CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667635-B2 | Bicyclic heterocycles as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | GAA 1654/4885LMNA 4388/4885DPYD 191/4885 |
| US-20220009921-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | GAA 1654/4885LMNA 4388/4885DPYD 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.